ABSTRACT
The successful development and application of mRNA COVID-19 vaccine fully illustrated the great potential and application prospect of mRNA technology in the field of biomedicine. Currently, many companies worldwide are developing drugs and vaccines based on mRNA technology for the prevention and treatment of various diseases. It can be foreseen that with the continuous launch of mRNA drugs, commercial GMP production capacity matching them is also urgent. The optimization of production processes, intelligent manufacturing and other risk control strategies, as well as the control of industrialization costs, will help improve the core competitiveness of mRNA innovative drug development. In view of this, this article will provide an overview of the global production process of mRNA drugs and the progress of related GMP production dynamics, sort out the key chain points of the mRNA industry chain, explore the construction of the mRNA pharmaceutical enterprise value chain and the formation of core competitiveness, and provide reference and reference for the research and development of innovative mRNA drugs and high-quality development in China.
ABSTRACT
Objective@#To grasp the present situation of occupational hazards of coal dust in our country, understand our country coal dust workers' occupational health risks, provide information based on evidence and analysis for the government and organize to effectively deal with the current status of high coal workers pneumoconiosis incidence in China, and protect coal dust workers' occupational health. @*Methods@#The research object is the " mining-transportation-use" of coal industrial chain, referring to 33 units. Use field investigation to obtain the coal dust exposure, dust prevention measures and the occupational health data of study object. Use quantitative evaluation method of International council on mining and metals occupational health risk assessment model (ICMM method) and occupational hazard risk index method (index method) , with coal workers pneumoconiosis as health outcomes, to evaluate the coal dust occupational health risks of coal industrial chain. @*Results@#The free silica content of partial coal dust in China is more than 10%, and even to 19.5%. coal dust concentration in workplaces, such as excavating system of dust coal mining (total dust: 22.1~46.5 mg/m3, respiratory dust: 8.4~17.7 mg/m3) , dumper (total dust: 25.2 mg/m3, respiratory dust: 6.9 mg/m3) , transfer tower (total dust: 35.4 mg/m3) of coal transportation and belt coal plough device of coal use (total dust: 36.3 mg/m3, respiratory dust: 14.0 mg/m3) , are much higher than those in other workplaces, and coal dust concentration of workers in these places (2.6~9.3 mg/m3) are much higher than those in other places, which are statistically significant. ICMM method evaluation results show that the risk value of excavating system is between 504~1 089, and the risk value of comprehensive mining system is between 347~2 040, which are far statistically significant higher than that of other systems. Index method evaluation results (excavating system risk value between 3.1~9.7, fully mechanized system risk value between 3.7~9.3) , are basically identical with ICMM method (correlation coefficient r=0.857, P<0.01) . The new cases of coal worker pneumoconiosis are distributed in three post of coal mining, excavating and coal mine mixing. @*Conclusion@#Coal-dust hazards are widely distributed in the coal "mining, transportation, and use" industrial chain, which of the underground coal mine is as serious as intolerable, meanwhile the risk of other industrial chain is basically can tolerable. The high coal dust concentration and the high risk of coal dust occupational hazard are concentrated in the excavating system and the comprehensive mining system. It is recommended to start the study on risk assessment and risk response of coal dust health hazard at the national level, and the occupational exposure limit of coal dust should be established according to the content of free silica.
ABSTRACT
Chinese medicine resources are the basis of the sustainable development of the health of Chinese medicine, and also the material basis for the sustainable development of Chinese medicine industry. Geoherbs are produced in the specific natural conditions, the ecological environment in the area of medicine. The quality of the medicinal materials is closely related to the characteristics of regional, diversity, variability, and humanity. It determines the particularity and regularity of the development of Chinese medicine resources. The effectiveness and safety of Chinese medicine are the core problems of the quality of Chinese medicine. However, the current Chinese medicine quality issues, quality evaluation, and control methods still exist and cannot objectively reflect the Chinese medicine problems in quality, quality standard in the determination and identification of components is not related with the effectiveness and safety. According to the relevance of the chemical constituents in Chinese medicines and plant secondary metabolite biosynthesis for reaction in herbs, herbal extracts, or compound preparation, and effects on the quality of medicinal materials, the author reiterated markers for defining the quality of traditional Chinese medicine basic conditions. Focus on the material foundation of characteristic, difference, and dynamic change in whole process and quality transfer and traceability, the author believes that to establish quality markers of drug industry chain whole process control system, is conducive to the establishment of a full Chinese medicine quality control and quality traceability system.
ABSTRACT
OBJECTIVE:To realize reasonable regression of Chinese medicinal material price to deal with Chinese medicinal material“nominal high price”. METHODS:From the perspective of whole industry chain management,reasons for Chinese medici-nal material“nominal high price”were discussed and feasibility analysis of whole industry chain management of Chinese medicinal material was carried out by using Macro-environment analysis(including politics environment,economic environment,social envi-ronment and technology environment). RESULTS & CONCLUSIONS:At present, Chinese medicinal material“nominal high price”mainly results from lack of core organization,supply deficiency,demand expansion,nonstandard storage and circulation and other factors. Relevant management departments and enterprises should set up whole industry chain management model of Chinese medicinal material from aspects of political environment,economic environment,social environment and technology environment, including to establish industry chain management organization core,to practice standardized production in the upstream industry chain,to appropriately extend industry chain for middle and downstream and to build up modernized logistics service system.
ABSTRACT
Chinese materia medica(CMM) industry is one of the most national identity in China′s industries.According to the development situation in recent years,putting forward some reasonable ideas will promote better and faster development of the CMM industry.In this paper,through the literature review combined with CMM industry development status,the current structure of CMM industry was analyzed.And based on the concept of the industrial chain,the CMM industry chain structure was analyzed and described.The proposal of building a harmonious CMM industry chain was put forward clearly,which will conform to the requirements of the CMM industry development.Above all,this article has provided some constructive ideas for future development of CMM industry.